Key Highlights
- SAB Biotherapeutics (NASDAQ: SABS) receives grant funding from Breakthrough T1D for its PRISE-hATG trial evaluating SAB-142 in Stage 3 type 1 diabetes patients.
- The trial targets patients diagnosed within 100 days to two years, focusing on insulin-dependent cases.
- H.C. Wainwright maintains a $10 price target on SAB Biotherapeutics shares.
- The announcement was disclosed in a regulatory filing dated July 7, 2026.
Grant Fuels Diabetes Trial
SAB Biotherapeutics (NASDAQ: SABS) announced a collaboration with Breakthrough T1D to advance its SAB-142 therapy for Stage 3 type 1 diabetes. The grant supports the PRISE-hATG clinical study, led by Dr. Michael J. Haller at the University of Florida, targeting patients recently diagnosed with insulin-dependent diabetes.
Trial Focus and Patient Criteria
The PRISE-hATG study evaluates SAB-142 in individuals aged 100 days to two years post-diagnosis. Stage 3 type 1 diabetes marks the point where insulin therapy becomes essential, representing a critical intervention window for potential disease-modifying treatments.
Breakthrough T1D Partnership
Breakthrough T1D, a global leader in type 1 diabetes research, awarded the grant to Dr. Haller’s team. The funding underscores confidence in SAB-142’s mechanism and its potential to alter disease progression in early-stage patients.
Regulatory and Market Context
The announcement was filed with the U.S. Securities and Exchange Commission on July 7, 2026. SAB Biotherapeutics emphasized forward-looking statements in the disclosure, noting risks and uncertainties that could impact clinical outcomes and financial performance.
Analyst Outlook
H.C. Wainwright reaffirmed its bullish stance on SAB Biotherapeutics, maintaining a $10 price target. The firm’s optimism reflects expectations for SAB-142’s clinical data and its broader pipeline in autoimmune therapies.
Forward-Looking Risks
SAB Biotherapeutics cautioned that trial results and regulatory approvals remain subject to variables beyond its control. Investors are advised to review the company’s risk disclosures in its latest SEC filings for a comprehensive assessment of potential challenges.
Competitive Landscape
The grant positions SAB Biotherapeutics alongside other biotech firms developing disease-modifying therapies for type 1 diabetes. Success in the PRISE-hATG trial could differentiate SAB-142 in a competitive field targeting early intervention.
FAQs
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...